Metropolis Healthcare: A three-year push to lift utilisation and margins

Metropolis Healthcare entered FY27 with a clear operating thesis: keep growth volume-led, sweat the network harder, and let mix and automation do the heavy lifting on margins. The company’s August 2026 investor meet put hard numbers behind that message. FY26 revenue from operations rose to 1,646 crore, with EBITDA of 401 crore and PAT of 191 crore. Management also drew an important distinction: reported FY26 EBITDA margin was 24.4%, but organic margin was 25.9%, with the difference attributed to the integration of Core Diagnostics, acquired at a stage when it was loss-making.

The tone of the presentation and transcript was consistent: Metropolis is not building its plan on price hikes. FY26 growth was described as volume-led with patient volume up 12% and test volume up 13%, with no price increase. That framing matters because the company’s FY27 revenue growth guidance of 14 to 15% explicitly assumes no price increase, and management pointed out that Q1 FY27 revenue growth of 17% was already ahead of that trajectory.

The operating footprint and where growth is coming from

Metropolis described itself as a national diagnostics network built over 45 years, with 209 laboratories and more than 5,000 collection centres. The company operates in 750+ towns across India and is also present in five international markets. FY26 revenue was split between B2C at 57% and B2B at 43%. Management’s positioning was straightforward: B2B keeps lab capacity full through hospitals, labs and corporates, while B2C helps build brand trust and supports stronger unit economics.

Geographically, revenue mix in the presentation was skewed to the West at 50%, followed by South at 27%, North at 18% and East at 5%. Management called out that North India has been scaling faster after acquisitions, and the Chairperson noted that North’s contribution could rise meaningfully over the next few years if it continues to outgrow other regions.

Financial summary

The company framed the past three years as broad-based profitable growth, with revenue CAGR of 17.6% over FY24 to FY26.

Strategy: five growth engines, one consistent theme

Metropolis’ three-year plan is built around five growth engines: network, TruHealth, specialty, technology, and inorganic growth, supported by science and talent. What stands out is that most of the growth is expected to come from assets already in place. Management repeatedly referenced utilisation as the margin lever, and volume as the growth lever.

On network, the company aims to expand owned centres toward 1,000 over three years and improve the centre-to-lab ratio from 24:1 toward about 35:1. The plan also includes about 100 mini-hubs, split between upgrades and new builds, intended to add basic radiology and consultation adjacencies. In the transcript, management described another utilisation angle: many owned centres see peak walk-in traffic in the early morning, and the company is exploring allied healthcare services to use the same real estate through the rest of the day.

TruHealth is the second engine, positioned as the company’s wellness and preventive bundle platform. The investor deck stated TruHealth at 18% of revenue today, with an ambition to reach 25%+ over three years. The company cited an average TruHealth ticket size of about 2,500 rupees and claimed wellness margins are in line with company averages. Management highlighted radiology packages, vitals, diet consultation and consult services as add-ons that can raise realisation without materially changing the cost base.

Specialty is the third engine, with a stated ambition to move specialty share from about 40% in Q1 FY27 to about 45% over three years. The company anchored the moat around interpretation and clinical confidence, not the availability of instruments. The presentation cited more than 2,200 specialty tests in the menu and 347 plus 36 tests added in FY26 and Q1 FY27. In genomics, Metropolis emphasised its two CAP-accredited genomics labs and clinician support for interpretation, arguing that interpretation capability is harder to replicate than sequencing capacity.

Technology is the fourth engine, split between digital experience on the front-end and automation across the lab and operations. The company stated digital share of revenue is now 25% and that 40% of B2C revenue comes from self-referrals. Management also described AI initiatives such as report summarisation and workflow automation, but with a cautious approach to ensure accuracy.

Inorganic growth is the fifth engine. The deck lists five acquisitions integrated and claims Core Diagnostics moved from about minus 2% EBITDA to high single-digit EBITDA within four quarters. The company’s stated M&A guardrails were clear: strong regional brand, ethical practices, positive unit economics, and disciplined entry valuation. Importantly, management reiterated that valuation discipline is critical in pathology because synergy economics are not comparable to pharma manufacturing consolidation.

Margin and capital agenda: 27 to 28% EBITDA is an execution target

The company’s medium-term margin ambition is to move EBITDA margin from 24.4% toward 27 to 28% over about three years. The investor deck laid out five levers: premiumisation through specialty and digital mix, higher centre-to-lab density, platform standardisation and vendor consolidation, cost efficiency through automation, and Core margin convergence to about 20%+ by year three.

Beyond the P&L, the capital agenda was framed around balance sheet efficiency. Management highlighted a target of single digit working capital days, supported by automated receivables, supply-chain digitisation, and a higher share of digital and cash collections. Capex was described as being held light at about 4% of revenue, with ROCE improvement positioned as the driver of shareholder value. The presentation also stated FY26 dividend was about 22% of PAT.

For FY27, management guided revenue growth of 14 to 15% and EBITDA margin improvement of 100 to 150 basis points, again noting the guidance assumes no price increase. Q1 FY27 metrics cited in the deck included revenue growth of 17% YoY and EBITDA margin of 25.2%, with management attributing momentum to B2C growth, specialty strength and faster expansion in Tier 3 towns.

Takeaways

Metropolis’ near-term story is unusually coherent for a diagnostics chain: grow volumes faster than the market using an already-built network, push specialty and TruHealth to lift realisation, and let automation and density improve utilisation-led margins. The company is also explicit about what must go right, including sustained volume growth, integration of acquisitions toward group margins, and stable regulatory and reimbursement conditions.

The next two to three years will test whether the plan can deliver 27 to 28% EBITDA margins while continuing selective M&A and experimenting with adjacencies like mini-hub radiology. If execution stays consistent, the company’s framework of volume, utilisation and capital compounding is designed to translate operating improvements into higher returns on capital, not just a higher margin headline.